Cook Group Goes to School in Cell Therapy

While a host of cardiovascular device companies are collaborating with gene and cell therapy firms in heart disease, Cook is taking a different approach to get in-house cell therapy expertise. It's created spin-off Cook Myosite, to develop the first cell therapy for urinary incontinence. Cook's urological division will sell the final product.

Since drug-eluting stents burst onto the market last year with the launch of Johnson & Johnson 's Cypher stent, there's been increasing talk of device companies and convergence--that is, a new paradigm in which devices will combine with therapeutic agents in the body to achieve biological, not merely mechanical, effects. The stent success has naturally focused the spotlight on interventional cardiology companies, where Boston Scientific Corp. , Medtronic Inc. and Johnson & Johnson are pushing even deeper into the realms of device-enabled biological solutions to heart disease, with gene and cell therapies for coronary revascularization (see "Cardiac Gene Therapy: Combination Products' Next Frontier?" START-UP, September 2003 Also see "Cardiac Gene Therapy: Combination Products' Next Frontier?" - Scrip, 1 September, 2003.) and cardiac regeneration (see "Convergence and Complexity in Cardiac Regeneration," START-UP, April 2004Also see "Convergence and Complexity in Cardiac Regeneration" - Scrip, 1 April, 2004.).

Device companies see in the new linkage with biology an opportunity to expand both horizontally and vertically, by broadening disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.